Reference standard is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
=== Global factors === Global factors, including climate change, armed conflicts (e.g., the war in Ukraine), and international market fluctuations, affect food prices worldwide. As Iran is a significant importer of food and agricultural inputs, these global trends directly affect its domestic pricing. In particular, increases in the prices of key commodities such as wheat, corn, and vegetable oils contribute to Iran's food inflation.
Wood is an organic material and decays under biological and chemical degradation when buried or submerged above water or soil. Wood, an organic material produced by plants, are chemically composed of: carbohydrates (cellulose and hemicellulose), lignin and other components (aliphatic acids, alcohols, proteins and inorganic substances) in a smaller amount. The most important composition of the plant is the cellulose. The cellulose accounts for the majority of the cell, about 40% to 50% of the wood's total mass. Hemicellulose represents the second most important carbohydrate and accounts for 20% to 30% of the wood's cell. In cases of extreme wetness or dryness, wood can be preserved until the extreme environment is disrupted. Conservation of wooden waterlogged objects is dependent on the natural wood type and biological structure. Wood is separated into two categories, hardwoods and softwoods. The category the waterlogged wood falls into can determine the amount of porous absorption. Hardwoods are classified as angiosperms. Angiosperms are considered porous woods because of the vessel pores. Softwoods are gymnosperms and are considered non-porous because of the lack of vessel pores. The type of wood and the availability of vessel pores largely affect how conservators treat and preserve waterlogged wood. Waterlogged wood objects can be found in a range of excavations sites. For example, waterlogged wood is something an archaeologist might stumble upon during an excavation either from the wood being submerged or near water or being in moist soil over time.
The mainstay of type 1 diabetes treatment is the regular injection of insulin to manage hyperglycemia. Subcutaneous injection using either a syringe multiple times a day, or with a continuous infusion insulin pump are necessary, adjusting dosages to account for food intake, blood glucose levels, and physical activity. The goal of treatment is to maintain blood sugar in a normal range—80–130 mg/dL (4.4–7.2 mmol/L) before a meal; <180 mg/dL (10.0 mmol/L) after—as often as possible. To achieve this, people with type 1 diabetes monitor their blood glucose levels at home. Around 83% of type 1 diabetics monitor their blood glucose by capillary blood testing: pricking the finger to draw a drop of blood, and determining blood glucose with a glucose meter. The American Diabetes Association recommends testing blood glucose around 6–10 times per day: before each meal, before exercise, at bedtime, occasionally after a meal, and any time someone feels the symptoms of hypoglycemia. 82% of people under 18 years old and 53% of those over 18 with type 1 diabetes use a continuous glucose monitor, a device with a filament under the skin that constantly measures glucose levels and communicates those levels to an external device as of 2025. Continuous glucose monitoring is associated with better blood sugar control than finger stick capillary blood testing alone; however, continuous glucose monitoring is much more expensive. Healthcare providers can also monitor someone's hemoglobin A1C levels, which reflect the average blood sugar over the last three months.
Estrogen has been found to increase the secretion of oxytocin and to increase the expression of its receptor, the oxytocin receptor, in the brain. In women, a single dose of ethinylestradiol has been found to be sufficient to increase circulating oxytocin concentrations.
==== 2022–present ==== In the early-to-mid 2020s, designer psychedelics such as 4-AcO-DMT (psilacetin) (found in mushroom edibles) and 4-HO-MET (metocin) and designer entactogens such as 5-MAPB have emerged and/or surged as openly marketed recreational drugs in the United States. In the early 2020s, safety and legal difficulty of regulating peptides spurred the growth of grey-market synthetic peptide hormone vendors. These peptides are marketed as non-recreational and sold for their purported anti-aging, performance enhancing and cosmetic benefits. Such vendors may employ medical professionals using legal ambiguity for their operations.
Sources: en.wikipedia.org
Flower delivery is a service in floristry. In many cases it is conducted through websites which allow consumers to browse online catalogues of flowers. They are often delivered to a third party, the recipient of the gift. Historically, these were coordinated through telegraphs and later telephones before the advent of the World Wide Web.
Graphene nanoribbons ("nanostripes" in the "zig-zag"/"zigzag" orientation), at low temperatures, show spin-polarized metallic edge currents, which also suggests applications in the new field of spintronics. (In the "armchair" orientation, the edges behave like semiconductors.)
Birches native to Eurasia include Betula albosinensis – Chinese red birch (northern + central China) Betula alnoides – alder-leaf birch (China, Himalayas, northern Indochina) Betula ashburneri – (Bhutan, Tibet, Sichuan, Yunnan Provinces in China) Betula baschkirica – (eastern European Russia) Betula bomiensis – (Tibet) Betula browicziana – (Turkey and Georgia) Betula buggsii – (China) Betula calcicola – (Sichuan + Yunnan Provinces in China) Betula celtiberica – (Spain and Portugal) Betula chichibuensis – (Chichibu region of Japan) Betula chinensis – Chinese dwarf birch (China, Korea) Betula coriaceifolia – (Uzbekistan) Betula corylifolia – (Honshu Island in Japan) Betula costata – (northeastern China, Korea, Primorye region of Russia) Betula cylindrostachya – (Himalayas, southern China, Myanmar) Betula dahurica – (eastern Siberia, Russian Far East, northeastern China, Mongolia, Korea, Japan) Betula delavayi – (Tibet, southern China) Betula ermanii – Erman's birch (eastern Siberia, Russian Far East, northeastern China, Korea, Japan) Betula falcata – (Tajikistan) Betula fargesii – (Chongqing + Hubei Provinces in China) Betula fruticosa – (eastern Siberia, Russian Far East, northeastern China, Mongolia, Korea, Japan) Betula globispica – (Honshu Island in Japan) Betula gmelinii – (Siberia, Mongolia, northeastern China, Korea, Hokkaido Island in Japan) Betula grossa – Japanese cherry birch (Japan) Betula gynoterminalis – (Yunnan Province in China) Betula honanensis – (Henan Province in China) Betula humilis or Betula kamtschatica – Kamchatka birch platyphylla (northern + central Europe, Siberia, Kazakhstan, Xinjiang, Mongolia, Korea) Betula insignis – (southern China) Betula karagandensis – (Kazakhstan) Betula klokovii – (Ukraine) Betula kotulae – (Ukraine) Betula luminifera – (China) Betula maximowicziana – monarch birch (Japan, Kuril Islands) Betula medwediewii – Caucasian birch (Turkey, Iran, Caucasus) Betula megrelica – (Republic of Georgia) Betula microphylla – (Siberia, Mongolia, Xinjiang, Kazakhstan, Kyrgyzstan, Uzbekistan) Betula nana – dwarf birch (northern + central Europe, Russia, Siberia, Greenland, Northwest Territories of Canada)) Betula pendula – silver birch (widespread in Europe and northern Asia; Morocco; naturalized in New Zealand and scattered locations in US + Canada) Betula platyphylla – (Betula pendula var. platyphylla) – Siberian silver birch (Siberia, Russian Far East, Manchuria, Korea, Japan, Alaska, western Canada) Betula potamophila – (Tajikistan) Betula potaninii – (southern China) Betula psammophila – (Kazakhstan) Betula pubescens – downy birch, also known as white, European white or hairy birch (Europe, Siberia, Greenland, Newfoundland; naturalized in scattered locations in US) Betula raddeana – (Caucasus) Betula saksarensis – (Khakassiya region of Siberia) Betula saviczii – (Kazakhstan) Betula schmidtii – (northeastern China, Korea, Japan, Primorye region of Russia) Betula sunanensis – (Gansu Province of China) Betula szechuanica – (Betula pendula var. szechuanica)—Sichuan birch (Tibet, southern China) Betula tianshanica – (Kazakhstan, Kyrgyzstan, Tajikistan, Uzbekistan, Xinjiang, Mongolia) Betula utilis – Himalayan birch (Afghanistan, Central Asia, China, Tibet, Himalayas) Betula wuyiensis – (Fujian Province of China) Betula zinserlingii – (Kyrgyzstan) Note: many American texts have B. pendula and B. pubescens confused, though they are distinct species with different chromosome numbers.
Most fatty acids in the trans configuration (trans fats) are not found in nature and are the result of human processing (e.g., hydrogenation). Some trans fatty acids also occur naturally in the milk and meat of ruminants (such as cattle and sheep). They are produced, by fermentation, in the rumen of these animals. They are also found in dairy products from milk of ruminants, and may be also found in breast milk of women who obtained them from their diet. The geometric differences between the various types of unsaturated fatty acids, as well as between saturated and unsaturated fatty acids, play an important role in biological processes, and in the construction of biological structures (such as cell membranes).
In a 2016 survey conducted by the Varkey Foundation and Populus, the question of whether or not those 15 to 21 favored legal migration received mixed responses. In the United States, that margin of support was 16%, higher than the global average of 8%. (See chart above.) According to Gallup, Americans aged 18 to 34 are more likely to view immigration as a "good thing" than their elders. By 2024, a clear majority of young adults supported increased patrols along the American-Mexican border to combat illegal immigration into the United States.
Sources: en.wikipedia.org
=== CDISC === The Clinical Data Interchange Standards Consortium leads the development of global, system independent data standards which are now commonly used as the underlying data structures for clinical trial data. These describe parameters such as the name, length and format of each data field (variable) in the relational database.
=== Design of globular proteins === Globular proteins are proteins that contain a hydrophobic core and a hydrophilic surface. Globular proteins often assume a stable structure, unlike fibrous proteins, which have multiple conformations. The three-dimensional structure of globular proteins is typically easier to determine through X-ray crystallography and nuclear magnetic resonance than both fibrous proteins and membrane proteins, which makes globular proteins more attractive for protein design than the other types of proteins. Most successful protein designs have involved globular proteins. Both RSD-1, and Top7 were de novo designs of globular proteins. Five more protein structures were designed, synthesized, and verified in 2012 by the Baker group. These new proteins serve no biotic function, but the structures are intended to act as building-blocks that can be expanded to incorporate functional active sites. The structures were found computationally by using new heuristics based on analyzing the connecting loops between parts of the sequence that specify secondary structures.
== History == Loperamide hydrochloride was first synthesized in 1969 by Paul Janssen from Janssen Pharmaceuticals in Beerse, Belgium, following previous discoveries of diphenoxylate hydrochloride (1956) and fentanyl citrate (1960). The first clinical reports on loperamide were published in 1973 with the inventor being one of the authors. The trial name for it was "R-18553". Loperamide oxide has a different research code: R-58425. The trial against placebo was conducted from December 1972 to February 1974, its results being published in 1977. In 1973, Janssen started to promote loperamide under the brand name Imodium. In December 1976, Imodium got US FDA approval. During the 1980s, Imodium became the best-selling prescription antidiarrheal in the United States. In March 1988, McNeil Pharmaceutical began selling loperamide as an over-the-counter drug under the brand name Imodium A-D. In the 1980s, loperamide also existed in the form of drops (Imodium Drops) and syrup. Initially, it was intended for children's usage, but Johnson & Johnson voluntarily withdrew it from the market in 1990 after 18 cases of paralytic ileus (resulting in six deaths) were registered in Pakistan and reported by the World Health Organization (WHO). In the following years (1990-1991), products containing loperamide have been restricted for children's use in several countries (ranging from two to five years of age). In the 1980s, before the US patent expired on 30 January 1990, McNeil started to develop Imodium Advanced containing loperamide and simethicone for treating both diarrhea and gas.
Trastuzumab emtansine, sold under the brand name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoes receptor-mediated internalization into cells, is catabolized in lysosomes where DM1-containing catabolites are released and subsequently bind tubulin to cause mitotic arrest and cell death. Trastuzumab binding to HER2 prevents homodimerization or heterodimerization (HER2/HER3) of the receptor, ultimately inhibiting the activation of MAPK and PI3K/AKT cellular signalling pathways. Because the monoclonal antibody targets HER2, and HER2 is only over-expressed in cancer cells, the conjugate delivers the cytotoxic agent DM1 specifically to tumor cells. The conjugate is abbreviated T-DM1. In the EMILIA clinical trial of women with advanced HER2 positive breast cancer who were already resistant to trastuzumab alone, it improved median overall survival by 5.8 months (30.9 months vs. 25.1 months) compared to the combination of lapatinib and capecitabine. Based on that trial, the U.S. Food and Drug Administration (FDA) approved marketing on 22 February 2013. Trastuzumab emtansine was developed by Genentech, and is manufactured by Lonza.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.